AR058296A1 - Inhibidores de histona desacetilasa y composicion farmaceutica - Google Patents

Inhibidores de histona desacetilasa y composicion farmaceutica

Info

Publication number
AR058296A1
AR058296A1 ARP060105429A ARP060105429A AR058296A1 AR 058296 A1 AR058296 A1 AR 058296A1 AR P060105429 A ARP060105429 A AR P060105429A AR P060105429 A ARP060105429 A AR P060105429A AR 058296 A1 AR058296 A1 AR 058296A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
group
aryl
alkyl
heteroaryl
Prior art date
Application number
ARP060105429A
Other languages
English (en)
Original Assignee
Kalypsys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalypsys Inc filed Critical Kalypsys Inc
Publication of AR058296A1 publication Critical patent/AR058296A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/30—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Estos compuestos son utiles para el tratamiento de estados de enfermedad incluyendo, pero sin limitarse a cánceres, enfermedades autoinmunes, dano tisular, desordenes del sistema nervioso central, anemias, talasemias, condiciones inflamatorias, condiciones cardiovasculares, y desordenes en los que la angiogénesis juega un rol en la patogénesis, utilizando el compuesto de la presente. Modulacion de la actividad de la deacetilasa e histona (HDAC). Reivindicacion 1: Un compuesto con la siguiente formula estructural (1) o una sal farmacéuticamente aceptable, éster o prodroga de la misma, caracterizado porque: G1 se selecciona de un grupo consistente en la sustitucion opcional de fenilo, opcionalmente sustituido en 5 o 6 grupo arilo, y opcionalmente sustituido en 5 o 6 grupo hetero-arilo; G2 se selecciona de un grupo consistente en una fraccion N-sulfonamida que tiene estructura (2), una fraccion S-sulfonamida que tiene estructura (3), una amida de la forma -NR3C(O)-, y una amida de la forma C(O)NR3-; G3 se selecciona de un grupo consistente en la sustitucion opcional de fenilo, sustituido opcionalmente en 5 o 6 grupo arilo, y opcionalmente sustituido en 5 o 6 grupo heteo-arilo; R1 y R2 se seleccionan cada uno independientemente del grupo consistente en H, alquilo inferior, halogeno y perhaloalquil, o R1 y R2 tomados juntos pueden formar un cicloalquilo opcionalmente sustituido o un heterocicloalquilo opcionalmente sustituido; R3 y R4 son seleccionados cada uno independientemente del grupo consistente en H, alquilo inferior opcionalmente sustituido, y arilo opcionalmente sustituido; G4 es seleccionado de un grupo consistente en -(CR5R6)m-, -(X1)n1O(X2)n2- -(X1)n1NR7(X2)n2-, -SO2-, - (X1)n1C(O)NR7(X2)n2-, y -(X1)n1NR7C(O)(X2)n, en las cuales cada uno puede ser opcionalmente sustituido con uno o más R9s ligados a cualquier átomo de C; 5 y R6 son seleccionados cada uno independientemente de un grupo consistente en H, alquilo opcionalmente sustituido, alcoxi inferior opcionalmente sustituido, arilo opcionalmente sustituido, y perhaloalquil inferior opcionalmente sustituido; R7 es seleccionado del grupo consistente en H, alquilo opcionalmente sustituido, heteroalquil opcionalmente sustituido, y alcoxi inferior opcionalmente sustituido; R9 es seleccionado del grupo consistente en alquilo inferior, alquilen inferior, alquinilen inferior, alcoxi inferior, amina inferior, halogeno, perhaloalquilo inferior, e hidroxilo; M es 1-6; X1 y X2 son seleccionados cada uno independientemente del grupo consistente en alquilen inferior opcionalmente sustituido, alquenileno opcionalmente sustituido, y alquinileno opcionalmente sustituido; n1 es 0-5; n2 es 0-5; G5 es seleccionado de un grupo consistente en arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, cicloalquenilo opcionalmente sustituido, arilo fusionado opcionalmente sustituido, heteroarilo fusionado opcionalmente sustituido, heterocicloalquil fusionado opcionalmente sustituido, y cicloalquilo opcionalmente sustituido; y G6 es seleccionado del grupo consistente en H, acilo opcionalmente sustituido, arilo opcionalmente sustituido, alquilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, alquiltio opcionalmente sustituido, ariltio opcionalmente sustituido y heteroariltio opcionalmente sustituido.
ARP060105429A 2005-12-09 2006-12-07 Inhibidores de histona desacetilasa y composicion farmaceutica AR058296A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74882305P 2005-12-09 2005-12-09
US80282306P 2006-05-22 2006-05-22

Publications (1)

Publication Number Publication Date
AR058296A1 true AR058296A1 (es) 2008-01-30

Family

ID=37895805

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105429A AR058296A1 (es) 2005-12-09 2006-12-07 Inhibidores de histona desacetilasa y composicion farmaceutica

Country Status (4)

Country Link
US (1) US20070135431A1 (es)
AR (1) AR058296A1 (es)
TW (1) TW200803852A (es)
WO (1) WO2007067994A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0411275A (pt) 2003-06-10 2006-08-01 Kalypsys Inc compostos de carbonila como inibidores de histona deacetilase para tratamento de doenças; composição farmacêutica; método de modular a atividade catalìtica de hdac; método de tratar doença em um indivìduo; utilização de um composto ou composição; método de inibir hdac
WO2005123089A2 (en) 2004-06-10 2005-12-29 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
EP1996233A2 (en) * 2006-02-27 2008-12-03 Gilead Colorado, Inc. Combinations comprising a histone deacetylase inhibiting agent and a nuclear hormone receptor ligand for treating cardiovascular conditions
WO2008073733A1 (en) * 2006-12-08 2008-06-19 Kalypsys, Inc. Salts of inhibitors of histone deacetylase for the treatment of disease
WO2008124699A1 (en) * 2007-04-06 2008-10-16 Nereus Pharmaceuticals, Inc. A method of using proteasome inhibitors in combination with histone deacetylase inhibitors to treat cancer
US8110550B2 (en) 2007-06-06 2012-02-07 University Of Maryland, Baltimore HDAC inhibitors and hormone targeted drugs for the treatment of cancer
WO2009126537A1 (en) * 2008-04-07 2009-10-15 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an hmt inhibitor
US8623853B2 (en) 2008-07-23 2014-01-07 The Brigham And Women's Hospital, Inc. Treatment of cancers characterized by chromosomal rearrangement of the NUT gene
PT2385938E (pt) 2009-01-12 2015-06-02 Pfizer Ltd Derivados de sulfonamida
CA2804173C (en) 2010-07-09 2015-01-13 Pfizer Limited Sulfonamide nav1.7 inhibitors
WO2012127466A1 (en) * 2011-03-24 2012-09-27 Bar Ilan University 5-aminolevulinic acid derivatives, methods for their preparation and uses thereof
US9481677B2 (en) 2011-10-31 2016-11-01 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
JP6014154B2 (ja) * 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
WO2013177224A1 (en) 2012-05-22 2013-11-28 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
WO2014008458A2 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
EP2968280A4 (en) 2013-03-14 2016-08-10 Genentech Inc SUBSTITUTED TRIAZOLOPYRIDINES AND METHOD OF USE THEREOF
WO2014144545A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
PE20161247A1 (es) 2013-11-27 2016-11-30 Genentech Inc Benzamidas sustituidas y metodos para usarlas
US10005724B2 (en) 2014-07-07 2018-06-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
CA2986045A1 (en) 2015-05-22 2016-12-01 Genentech, Inc. Substituted benzamides and methods of use thereof
JP2018526371A (ja) 2015-08-27 2018-09-13 ジェネンテック， インコーポレイテッド 治療化合物及びその使用方法
PE20181003A1 (es) 2015-09-28 2018-06-26 Genentech Inc Compuestos terapeuticos y sus metodos de uso
WO2017091592A1 (en) 2015-11-25 2017-06-01 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
EP3436432B1 (en) 2016-03-30 2021-01-27 Genentech, Inc. Substituted benzamides and methods of use thereof
RU2019114964A (ru) 2016-10-17 2020-11-17 Дженентек, Инк. Терапевтические средства и способы их применения
US10793550B2 (en) 2017-03-24 2020-10-06 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
KR102236356B1 (ko) 2017-11-24 2021-04-05 주식회사 종근당 루푸스의 예방 또는 치료를 위한 조성물
AR114263A1 (es) 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
CN111936494A (zh) 2018-03-30 2020-11-13 豪夫迈·罗氏有限公司 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪
KR20190118251A (ko) * 2018-04-10 2019-10-18 주식회사 종근당 건성안의 예방 또는 치료를 위한 조성물
TW202029962A (zh) * 2018-10-26 2020-08-16 法商量子基因科技有限公司 胺肽酶a抑制劑及包含其的醫藥組合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7071220B2 (en) * 2000-09-18 2006-07-04 Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivatives
BRPI0411275A (pt) * 2003-06-10 2006-08-01 Kalypsys Inc compostos de carbonila como inibidores de histona deacetilase para tratamento de doenças; composição farmacêutica; método de modular a atividade catalìtica de hdac; método de tratar doença em um indivìduo; utilização de um composto ou composição; método de inibir hdac
GB0402380D0 (en) * 2004-02-03 2004-03-10 Argenta Discovery Ltd Novel compounds
WO2005123089A2 (en) * 2004-06-10 2005-12-29 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
WO2006063294A2 (en) * 2004-12-09 2006-06-15 Kalypsys, Inc. Novel inhibitors of histone deacetylase for the treatment of disease
US20070027184A1 (en) * 2005-07-29 2007-02-01 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease

Also Published As

Publication number Publication date
TW200803852A (en) 2008-01-16
WO2007067994A1 (en) 2007-06-14
US20070135431A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
AR058296A1 (es) Inhibidores de histona desacetilasa y composicion farmaceutica
ES2528451T3 (es) Inhibidores de esfingosina cinasa
PE20151651A1 (es) Derivado de tetrahidroimidazol[1,5-d][1,4]oxazepina
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
AR083946A1 (es) Metodos de tratamiento con inhibidores selectivos de bcl-2
BRPI0515546A (pt) compostos para inflamação e usos imune-relacionados
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
AR063015A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer
AR061923A1 (es) Compuestos derivados de benzofuran-piperidina
CO6290658A2 (es) Derivados de azetidina y ciclobutano como inhibidores de jack
AR041635A1 (es) Compuestos de 4-piperazinilbencenosulfonilindoles, preparacion de los mismos y composiciones farmaceuticas que los contienen
TW200716108A (en) Thiophene compounds for inflammation and immune-related uses
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
MX2007008957A (es) Compuestos para usos relacionados a inflamacion de inmunidad.
PE20061076A1 (es) Derivados de isoxazolina como agentes inhibidores de la caspasa y procedimiento para su preparacion
AR065622A1 (es) Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona
AR056762A1 (es) (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos
AR101177A1 (es) Inhibidores de la syk
EA200901162A1 (ru) Производные 1,4-дизамещённого 3-цианопиридона и их применение в качестве положительных модуляторов рецептора mglur2
PE20180030A1 (es) Compuestos biciclicos de sulfonamida cetona
ATE552246T1 (de) Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten
EA200700909A1 (ru) Азаиндолкарбоксамиды
AR059952A1 (es) Derivados de bencenosulfonilamin- piridina inhibidores de histona desacetilasa
AR040278A1 (es) Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos
AR041440A1 (es) Lactamicos y sus usos

Legal Events

Date Code Title Description
FB Suspension of granting procedure